Datapoint: BMS Faces Generic Revlimid Competition With Teva Launch

Teva Pharmaceuticals this week launched Lenalidomide, a generic alternative to Bristol Myers Squibb’s Revlimid, for the treatment of multiple myeloma. It is the first of several generic challengers to launch. For the treatment of multiple myeloma, Revlimid currently holds covered or better status for 99% of all insured lives. 17.6% of all covered lives have preferred access to Revlimid without utilization management restrictions.

SOURCE: MMIT Analytics, as of 3/8/22

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
January 26

Datapoint: Elevance Health to Acquire BCBS Louisiana

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
January 25

Datapoint: Seagen Scores Colorectal Cancer Nod for Tukysa

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
January 24

Datapoint: Georgia Doubles Down on Partial Medicaid Expansion Waiver

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today